Corxel Pharmaceuticals raised $287 million in a Series D1 financing to accelerate development of CX11, an oral small‑molecule GLP‑1 receptor agonist targeting obesity and type 2 diabetes. The company reported positive Phase II weight‑loss signals (around 9–10% at 16 weeks) and is running a US Phase II and a China Phase III, positioning CX11 as a potential oral alternative to injectable GLP‑1s. Investors including RTW and SR One backed the round, which Corxel said will fund global development and commercial preparation. The financing highlights continued investor appetite for oral GLP‑1s after regulatory moves approving pill formulations raised commercial expectations.